Novo Nordisk has announced the international launch of a new pre-filled syringe offering for its haemophilia therapy NovoSeven.
The product will be released under the brand names NovoSeven with pre-filled syringe in Europe and NovoSeven RT with MixPro in the US, having received approval from the relevant regulatory bodies in October 2012.
It supports the rapid treatment of bleeding episodes in haemophilia patients with inhibitors and offers advantages in terms of speed of reconstitution, ease of use, reliability and portability.
These benefits are underpinned by the fact that it is no longer necessary to draw the solvent into the syringe separately.
Paul Huggins, corporate vice-president for global biopharmaceutical marketing and medical affairs at Novo Nordisk, said: "Novo Nordisk constantly strives to make advancements for patients. With this latest development we show our commitment to improve the lives of people with haemophilia in every way possible."
This comes in the same week that the company announced that its type 1 and type 2 diabetes therapy Tresiba has been approved to launch in Japan.See all the latest jobs in Pharmaceutical